The Board of Directors has been meticulously curated to support Linio Biotech, an innovative R&D company, in executing its vision, creating strategic partnerships for growth, and bringing in the expertise essential for commercialising and developing next-generation products for global markets.
Linio Biotech’s core innovation, Tience®, is a breakthrough in regenerative aesthetics. It treats aging skin and skin defects by stimulating the skin’s natural ability to heal. Tience® is the first innovation capable of harnessing the natural reparative potential of human adipose tissue in an allogenic ready-to-use injectable product. Tience® is a non-invasive procedure delivered through an intradermal injection in a short walk-in procedure with minimal downtime. Among its effects, Tience® induces the formation of collagens by fibroblasts up to tenfold without any inflammatory reaction from foreign bodies. Tience® also contributes to skin renewal by activating mesenchymal stem cell proliferation, migration, and differentiation. The innovation is already available in over 30 clinics in Finland and Sweden, with the ambition of achieving triple-digit growth.
The new board members bring a wealth of experience and specialised knowledge across key areas, vital to Linio’s mission:
- Chairman of the Board, Timo Lappi: Timo’s drive to create top-performing boards, build corporate governance practices fit for growth, and his legal expertise are instrumental for both the board and the company. Timo thrives on building challenger companies, developing new value propositions, and creating great workplaces, all powered by digitalisation.
- Benoit Chardon: Benoit’s track record in successful new category creation in the medical aesthetics field, brand building, hyper-growth, and M&A will play a strategic role in enabling Linio to build value by positioning its innovation pipeline compellingly, with the right partners and commercial capabilities.
- Ilkka Laurila: Ilkka brings a strong track record in creating profitable growth and possesses in-depth knowledge of financial arrangements and value creation across various industries. The company looks forward to Ilkka’s leadership in scaling operations and designing cost-effective structures to support growth.
- Jaana Linna: Jaana brings expertise not only in launching best-in-class products to market but also in people and talent strategies. The company aims to align the growth of its people, organisation, and business under her guidance.
- Didier Leclercq: Based in New York, Didier has vast knowledge and a long professional history in managing the entire Galderma medical aesthetic business and leading ambitious R&D efforts in new product development. His technical and leadership expertise in the specific field aligns perfectly with Linio’s ambition to develop next-generation products leveraging Tience® as a platform technology and will be a catalyst for our success going forward.
These roles were established through a comprehensive evaluation project led by members of the legacy board and facilitated by Boardman Oy. Read more about Tience® here: www.tience.com
